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Abstract 
Falciparum malaria persists in hard-to-reach areas or demographic groups that are missed by conventional healthcare 
systems but could be reached by trained community members in a malaria post (MP). The main focus of a MP is to 
provide uninterrupted and rapid access to rapid diagnostic tests (RDTs) and artemisinin-based combination therapy 
(ACT) too all inhabitants of a village. RDTs allow trained community members to perform malaria diagnosis accu-
rately and prescribe appropriate treatment, reducing as much as possible any delay between the onset of fever and 
treatment. Early treatment with ACT and with a low-dose of primaquine prevents further transmission from human 
to mosquito. A functioning MP represents an essential component of any malaria elimination strategy. Implementing 
large-scale, high-coverage, community-based early diagnosis and treatment through MPs requires few technological 
innovations but relies on a very well structured organization able to train, supervise and supply MPs, to monitor activ-
ity and to perform strict malaria surveillance.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Despite recent significant progresses towards elimination 
in several countries in Asia, Africa and South America, 
malaria remains a major health issue in many tropical 
regions where it thrives in countries with a weak health-
care system [1]. In the last 20 years significant increases 
in investment have resulted in the development of new 
tools to combat this parasitic disease, the most common 
of mankind. Some of the newest tools require expen-
sive and complex technologies that are not available to 
national malaria programmes, or are still under trial (vac-
cines, insecticides, genetically modified mosquitoes) [2]. 
Others are already available, such as long-lasting insecti-
cidal bed nets (LLINs), rapid diagnostic tests (RDTs) and 
artemisinin-based combination treatment (ACT). Their 
large-scale deployment probably explains most of the 
decrease in malaria-related morbidity and mortality in 
Southeast Asia and Africa as well as renewed interest in 
malaria elimination [3–5]. However, in order to control 
malaria (reduction of morbidity and mortality) and elimi-
nate it (interruption of the transmission cycle), it is 
essential to identify and treat infected individuals early in 
the course of the illness. To achieve this goal, everyone 
living in malaria-endemic areas must have easy access to 
reliable diagnostics and effective treatment. This is one of 
the most difficult tasks encountered by national malaria 
programmes.
The aim of the present article is to discuss in detail the 
concept of early diagnosis and treatment (EDT) of falci-
parum malaria cases. First, the rationale for community-
based EDT and the concept of the malaria post (MP) are 
presented. Second, the novelties in tools and approaches 
for the successful deployment of MPs are detailed. Third, 
evidence of the impact of widespread deployment of 
community-based EDT is described, followed by the 
requirements for regional integration of an MP network 
as part of a falciparum malaria elimination strategy. 
Finally, an outline of the challenges to be met to ensure 
the sustainability of EDT by MPs is provided.
Rationale for community‑based EDT
EDT provides a means of decreasing transmission of 
Plasmodium falciparum from symptomatic individuals. 
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In P. falciparum infections symptoms usually occur 
when the density of asexual parasites reaches a pyro-
genic threshold, approximately 12–14 days after an infec-
tive bite [1]. Mature gametocytes are the sexual stages 
that are infective for mosquitoes. They emerge seven to 
15 days after the onset of symptoms [6]. Treating P. falci‑
parum-infected patients within 24–48 h after fever onset 
is likely to prevent further transmission of the parasite. 
Conversely, patients who delay treatment are more likely 
to remain infectious even after being treated because 
gametocytes may persist for several weeks after clear-
ance of asexual parasites [7, 8]. Patients who experience 
a recurrence of their infection because they received an 
ineffective or incomplete treatment have higher gameto-
cyte carriage and contribute disproportionately to trans-
mission [9].
The malaria post
Most healthcare delivery systems have a concentric 
structure centred on a referral hospital. At the periph-
ery are dispensaries or health posts where people from 
surrounding villages go when they are ill. But indi-
viduals living in endemic regions face many barriers 
to accessing malaria diagnosis and treatment because 
of geographic distances or travel difficulties, as well as 
socio-cultural, economic, political, and legal factors 
[10–14]. Most of these problems can best be addressed 
through diagnosis and treatment based within the com-
munity [10, 15–17].
Community-based EDT for malaria is implemented 
through a simple structure: the malaria post (MP). An 
MP is defined by three main criteria: (1) trained per-
sonnel; (2) quality RDT; and, (3) effective anti-malarial 
drugs. The MP is a simple structure that provides con-
tinuous access to reliable diagnosis and effective treat-
ment for any clinical malaria cases from the community 
within 24–48 h of fever onset. The minimalistic nature of 
the MP makes it feasible to set up and maintain in dif-
ficult settings where malaria persists. An effective MP 
presents several important particularities: it offers free 
services and continuous availability of staff and supplies; 
it ensures diagnosis and treatment of clinical malaria; and 
it is part of a dense network designed to have an impact 
on malaria at the regional level. These attributes allow 
large-scale implementation of efficient malaria EDT by 
MP in almost any setting. A network of MP is the neces-
sary backbone on which to build a P. falciparum malaria 
elimination programme (Fig.  1). MP should be located 
within an easy walking distance (e.g., 15  min) from any 
home, keeping in mind that a short geographical distance 
is a necessary factor for access, but not sufficient if social, 
behavioural and other barriers are overlooked.
Costs and cost‑effectiveness of MP for malaria elimination
Apart from ACT and RDTs, an MP requires very little 
equipment: pregnancy tests and antimalarial treatment 
for pregnant women, paracetamol for non-malaria fever, 
a watch or clock to ensure timely reading of RDT and a 
scale for ACT dosing (see Additional file 1 for a complete 
list of supplies). MPWs should be provided with a refer-
ence handbook, including drug-dosing tables and deci-
sion algorithms. Used RDTs should be collected monthly 
for quality control and adequate disposal. In the large-
scale deployment of EDT in Eastern Myanmar realized by 
the METF (Fig. 1), the monthly cost of an MP is around 
US$160, including the management of the MP network 
(Fig. 2) [18]. Community-based treatment, LLIN deploy-
ment and combined strategies have been assessed in a 
modelling work in the context of Southeastern Myanmar. 
In a malaria control perspective, the combined strategy 
was the most cost-effective, especially in communities 
where access to healthcare was difficult, even though 
transportation costs increased [19]. In METF, costs of MP 
are compatible with estimated values of standard commu-
nity health workers in Myanmar, although the distribution 
of these costs differs significantly (Fig. 2) [20].
New tools and approaches driving MP efficacy
RDTs
In the 1950s, pioneering programmes in Latin America 
and Southeast Asia relied on village-based volunteers to 
collect blood smears of suspected cases. Since micros-
copy was the only diagnosis confirmation available, vol-
unteers had to provide presumptive treatment or to refer 
to a central or mobile microscopy-equipped facility for 
diagnosis confirmation, resulting in delayed treatment 
[21]. Populations living in remote areas were frequently 
neglected. Today RDTs overcome many bottlenecks 
encountered by microscopy: it is faster to train unskilled 
personnel to use RDTs than to train a good microscopy 
technician; there is no ‘fatigue’ or loss of blood smear 
reading skills because of a rarity of positive cases in a 
context of decreasing incidence; and, RDTs are easy to 
supply [22, 23]. Recent systematic reviews have con-
cluded that RDT interpretation and performance are sat-
isfactory when handled by trained community members 
and can result in the appropriate prescription of ACT for 
confirmed P. falciparum cases [24–26]. Recent improve-
ments in RDT sensitivity and specificity mean that they 
perform as well as microscopy for symptomatic falcipa-
rum malaria infections in many settings [27]. RDTs can 
reliably discriminate between P. falciparum and P. vivax 
infections [22, 28, 29]. The good performances achieved 
by RDTs should be taken as strong encouragement to 
further develop this tool. For example, it is crucial to 
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work on the detection of P. falciparum parasites lack-
ing PfHRP2. These parasites are of concern in South 
America and should be monitored elsewhere to ensure 
the sustained efficacy of the RDT in use [30]. Addition-
ally, it is important to improve the specifications of RDTs 
so that results can remain readable over a longer time 
period to facilitate monitoring of activities and quality 
control.
ACT and low‑dose primaquine
ACT rapidly kills asexual stage P. falciparum parasites, 
preventing gametocytogenesis [31, 32]. Artemisinins 
are also active against stages I–IV gametocytes but not 
against the mature infectious gametocytes (stage V) [9, 
33–35]. These forms develop in patients who present late 
for treatment, making such patients important sources of 
transmission [31]. Primaquine is the only currently avail-
able anti-malarial active against mature P. falciparum 
gametocytes [36]. The single, low dose recommended 
by WHO is unlikely to cause severe haemolytic anaemia 
even in individuals with G6PD deficiency [37]. When 
administered early in the course of the disease in combi-
nation with an ACT it shows a dramatic effect on trans-
missibility of P. falciparum [36, 38].
In many regions, the efficacy of malaria treatment is 
threatened by the use of counterfeit or sub-standard 
drugs [39]. Widely available quality drugs limit the num-
ber of patients exposed to sub-therapeutic doses of anti-
malarials, contributing to the fight against the emergence 
and the selection of drug-resistant parasites.
Trained and supported MP workers
Malaria post workers (MPW) should be members of the 
community that they will serve, and should be selected by 
their peers. They should have at least some basic education 
and should have previously shown some interest in health-
related work. MPWs must have an occupation that does 
not require them to leave their village for more than a day 
at a time. Their training should include an introduction to 
malaria, the use of RDT and ACT, when to refer patients, 
and the recording and reporting of their activities (Table 1). 
In order to maintain an adequate standard of care, close 
Fig. 1 Map of the region of Eastern Myanmar targeted for large scale deployment of community-based EDT by the Malaria Elimination Task Force 
(METF). Drug and multidrug-resistant falciparum malaria is a major threat in the Thailand-Myanmar border region. In the past drug-resistant malaria 
has emerged in this area, and other parts of Southeast Asia, and subsequently spread globally. Elimination of falciparum malaria in the region is 
the only solution to avoid a repeat of history with artemisinin resistance. With this goal in mind, the METF was set up in 2014 and targets over 1200 
villages in Eastern Kayin State, Myanmar [18]. The high-level divisions (area, zone) are represented. Each zone corresponds to a territory under the 
responsibility of one health community-based organization
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supervision and regular quality control of RDT results are 
necessary, especially during the initial weeks and months 
after an MP opening [40, 41]. This allows for retraining or 
replacement of MPWs if necessary. MPWs should receive 
fair compensation for their activities and constant avail-
ability [26]. Community-based programmes often rely on 
unpaid volunteers or provide activity-based compensation 
(e.g., per consultation or per RDT) but these types of incen-
tives are not adapted to a context of highly seasonal illness 
or expected decreases in malaria incidence throughout an 
effective elimination programme. While some individuals 
may find it extremely rewarding to provide health services 
to their community on a voluntary basis [25, 40], remuner-
ation of MPWs can promote objective-driven motivation 
and drastically reduce attrition and corruption.
In some settings, private drug retailers might already 
exist in a community. In a context of malaria elimina-
tion, provision of free EDT to rare malaria cases will not 
represent a significant loss of income to such drug retail-
ers. If they provide a valuable health service, it is desir-
able that this service should be monitored and quality 
assured. As any other member of the community meeting 
the requirements, they can be appointed as MPWs if they 
agree to be trained and to follow MP principles.
Community engagement
Taking into account local context is crucial to setting up a 
quality service that becomes a long-term part of commu-
nity life [42]. This observation is not new but increased 
awareness that village-based EDT programmes will fail 
unless there is acceptance and support from the popula-
tion has led to the promotion of active engagement strat-
egies [43]. The community engagement (CE) team must 
have a deep understanding of the local population and 
develop and maintain trust with the community. They 
should meet with the people, their leaders and represent-
atives in order to explain the objectives, technicalities and 
benefits of the MP. Unlike past attempts at community-
based malaria interventions, the MP can provide care to 
uncomplicated malaria cases without delay or referral 
[21]. Entrusting this responsibility to the community rep-
resents a significant step of empowerment especially for 
vulnerable or marginalized populations.
Large‑scale deployment of community‑based EDT 
for falciparum elimination
Evidence of the impact of the deployment 
of community‑based EDT with ACT
Reports from a wide range of spatial and demographic 
scales in various geographic settings describe downward 
trends in clinical falciparum malaria incidence after the 
deployment of EDT using ACT and RDTs over the last 
15 years [3, 4, 44]. Monitoring in settings where EDT has 
been consistently available over long periods of time sug-
gests that EDT in combination with vector control meas-
ures can achieve near-elimination of falciparum malaria. 
Fig. 2 Distribution of monthly costs in an METF-supported MP. 
Costs of METF MP are around US$160, similar to other programs 
in Myanmar [20]. The costs of training, transportation (supervision, 
supply, patient referrals), data transmission (smartphone and SMS) 
and management of the MP network (36 % of total), emphasize the 
necessary investment on constant availability of supplies, regular 
monitoring and weekly malaria surveillance in MP. Stock-outs, lack 
of refresher trainings and/or monitoring visits have been reported as 
major risks for losing the trust of the communities and demotivation 
of workers in other programs of malaria EDT [40, 41], and are a major 
threat to elimination programs (see also “Challenges” section)
Table 1 Malaria post worker (MPW) training and tasks
Training
 Recognize signs of malaria
 Conduct and interpret rapid test results
 Observe universal precautions
 Record, report and transfer results (weekly)
 Knowledge on where to refer severe cases (local clinic)
Tasks
 Stay in the village and be able to treat malaria within 24 h of fever 
onset. Make sure village population is aware of the existence of the 
MP
 Administer drugs to patients according to protocol (including adher-
ence monitoring if not directly observing treatment)
 Monitor patient’s condition and recognize side effects
 Refer severe cases and possible treatment failures to nearest health 
centre
 Weekly check stocks and transmit appropriate orders to supervisor
 Keep working environment clean and safe
 Detect and report all malaria cases to supervisor
 Engage community on malaria-related public health issues (e.g., use of 
LLIN or other vector control)
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On the Thai-Myanmar border, 15 years of EDT with ACT 
in clinics serving migrant and displaced populations drasti-
cally reduced the incidence of falciparum malaria [45, 46]. 
Malaria elimination efforts in Thailand were largely effec-
tive for much of the central plains region of the Kingdom 
but deteriorated with distance [47]. Tak Province is an 
example of a remote malarious region along the Thailand-
Myanmar border. In 2001–2002 a community-based EDT 
strategy (The Tak Malaria Initiative) was deployed in all 
five sub-districts of the province [48]. In addition to the 92 
existing provincial health facilities, 100 community-based 
malaria treatment posts were set up in villages and areas 
where access to health services was low. Over the follow-
ing 2  years clinical P. falciparum incidence was reduced 
by 54 %, malaria-related deaths by 52 % and P. falciparum 
prevalence was significantly lower in intervention villages 
in comparison to controls [48]. Malaria vectors were still 
present but the entomological inoculation rate (EIR) was 
very low [48]. In Asia, similar declines in morbidity and 
mortality were reported from Cambodia after country-
wide implementation [49]. Reports of ACT deployment 
on the African continent are equally encouraging: in the 
quasi-experimental setting of Dielmo village in Senegal, 
deployment of ACT at a local clinic in 2006 and mass 
distribution of LLINs in 2008 impacted both P. falcipa‑
rum incidence and prevalence so drastically that in 2012 
malaria was nearly eliminated [50]. Deployment of com-
munity-based EDT was also followed by decreases in P. 
falciparum-related morbidity, mortality and re-infection in 
clinical trials [24–26]. After regional implementation, simi-
lar decreases in incidence of morbidity and mortality were 
observed in Kwazulu-Natal [44] and a decreased prevalence 
of P. falciparum infection was reported from Ethiopia [5].
Requirements for regional integration in an elimination 
strategy
Even if a significant impact can be measured at vil-
lage scale, the largest and longest term impacts towards 
elimination can only be achieved if the MP programme 
is deployed in all villages of a region (i.e., a geographical 
unit defined by a population, political boundaries and 
accessibility criteria). Coordination at regional (prov-
ince, district, state) and central administrative levels of a 
country offers a wide geographical spread, the ability to 
take local specificities into account (different seasonal-
ity, for example) with relevant administrative divisions to 
interface with the health system in place. It is, however, 
advisable to always adapt divisions of a programme to 
local constraints, especially in peripheries and on borders 
where the population is usually less well covered.
Exhaustive mapping of  communities in  target 
region Detailed data on the distribution of human set-
tlements across malarious landscapes are frequently lack-
ing making it difficult or impossible to know the true 
malaria burden and or the healthcare needs. Systematic 
geographic and demographic surveys are therefore a 
prerequisite to acquire accurate baseline data. Prior to 
the deployment of a network of MP, a detailed map of 
all communities in the target region must be drawn with 
geographic coordinates and estimated numbers of house-
holds for all settlements, the location of existing health 
facilities and access to communication networks (Fig. 1). 
This step is crucial to ensure that MPWs are deployed in 
all human settlements and not according to perceived 
access or other biased measures. It also allows for docu-
mentation of higher-level health structures on which the 
MP support system can rely and to build a geographic 
information system to follow the implementation of the 
programme and its efficiency.
Malaria surveillance and  MP activity monitoring 
through real‑time data reporting Reporting of cases and 
inventory is key for surveillance and logistics. Information 
can be collected quickly on smartphones using dedicated 
entry forms, and transmitted effortlessly through inter-
net or SMS in regions where phone network is available 
[51, 52]. In regions lacking a phone network, paper data 
sheets can be effectively collected and transported to cen-
tral collection and data entry points. Weekly analysis of 
malaria incidence reports allows identification of com-
munities where falciparum malaria is not following the 
expected decreasing trends. Spatio-temporal analysis of 
weekly incidence reports allows regional-scale assess-
ment of villages or clusters of villages where persisting or 
higher-than-expected P. falciparum incidence is detected 
and to adjust the magnitude of targeted interventions in 
response [53, 54]. Analysis of weekly MP reports also pro-
vides alerts on possible MP malfunction or interruption 
of service (missing reports, lack of activity, supply short-
age, etc.), which is used to target supervision visits.
Integration within the regional health system network In 
many nations the health care system does not reach all 
communities. The MP network is specifically designed 
to address this critical gap, while avoiding redundancies. 
If there are available healthcare units (e.g., health clin-
ics), these can be used as focal points for MP located in 
surrounding villages. They will be the referral centre for 
patients that cannot be treated at MP. They can also act 
as the last logistic node: dispatch MP supplies, collect and 
transmit weekly data reports. The medical staff can super-
vise MPW activities. At higher levels, health districts and 
sub-districts can handle the supervision of the network 
(MPW training, MPW monitoring and supervision) and 
its management (logistic, financial, administrative). Like-
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wise, data collection and surveillance tasks can be inte-
grated within an existing health management informa-
tion system (HMIS) if it is able to sustain the frequency of 
reporting and timeliness required for malaria elimination 
surveillance. Alternatively, a specific system can be set 
up. As it is relying on high-resolution spatial and tempo-
ral data, it can easily be interfaced with existing report-
ing frameworks and can also become the backbone of a 
future HMIS.
Challenges
Maintaining the MP and the network
The main challenges are to continuously maintain MP 
supplies, to ensure regular collection of accurate and 
complete data records and to monitor the activities 
of MPWs and the quality of services, as was recently 
described in studies of village health workers perform-
ing malaria EDT in Myanmar [40, 41]. Real-time, spa-
tially explicit monitoring of activity and surveillance, as 
described in the previous section, will only be relevant if 
a strong organization with deep local roots and a dense 
network is acting in the field to conduct routine activi-
ties and follow-up on alerts. This organization can merge 
with and benefit from existing health structures where 
possible. Community engagement at regional level will 
involve coordination with community-based organiza-
tions, governmental and traditional authorities.
Vertical malaria-centred treatment is necessary to 
properly address persistent falciparum malaria in places 
where it has otherwise been difficult or impossible to 
eliminate. Over 90 % of malaria resurgence events were 
at least partly associated with failure to maintain malaria 
control programme interventions [55]. MPWs may lose 
focus, motivation or become complacent when falcipa-
rum malaria cases become increasingly rare [40]. MP will 
remain at the centre of the elimination strategy in regions 
where P. vivax is also present. In other areas it may be 
necessary to switch to integrated community case man-
agement (ICCM) of additional diseases in order to retain 
the focus on EDT for all potential malaria patients [40]. 
ICCM can increase public health relevance and cost 
effectiveness of the MP in a malaria elimination setting, 
where costs per case treated by an MP are expected to 
rise as malaria cases decrease [56, 57]. ICCM represents 
an additional step in community-based health provision 
and new activities can benefit from training, supervision, 
reporting, and logistic backbone already implemented for 
malaria elimination.
P. falciparum drug resistance
Malaria has decreased several times before in history and 
gains were lost when drug-resistant P. falciparum arose 
[45, 50, 58]. The development of chloroquine resistance 
in falciparum malaria and its subsequent spread glob-
ally inflicted a catastrophic blow to elimination efforts. 
Collection of P. falciparum-positive RDTs or additional 
collection of dried blood spots from all MP or from a 
selection of sentinel sites, allows the monitoring of mark-
ers of resistance to artemisinin (K13 polymorphism) 
as well as partner drugs (e.g., PfMDR1 for mefloquine/
lumefantrine) [59–61]. Treatment and containment strat-
egies can then be developed and implemented based on 
the drug resistance surveillance network.
Vivax malaria
If complete malaria elimination is the goal, vivax malaria 
must be eliminated in regions where it is prevalent. A dif-
ferent approach from that used for P. falciparum elimina-
tion is required because of differences in the life cycle of 
the two parasites. A typical MP is only equipped to treat 
the asexual blood stages of P. vivax. Plasmodium vivax 
gametocytes emerge much earlier in the course of an 
infection, sometimes prior to clinical presentation. EDT 
is therefore not expected to be as efficient at breaking the 
transmission cycle of P. vivax compared with P. falcipa‑
rum [8, 62]. Plasmodium vivax is characterized by liver-
stage hypnozoites which cause relapsing blood-stream 
infections without exposure to new infective bites. These 
hypnozoites are not killed by chloroquine and relapses 
are therefore not prevented by early treatment at the MP 
[63]. The only available treatment for the radical cure for 
P. vivax is a 14-day course of primaquine but it is rarely 
used because of poor adherence and potential toxicity 
in case of G6PD deficiency [64, 65]. Point-of-care G6PD 
tests and better treatments of the hypnozoites are needed 
to eliminate P. vivax.
Conclusions
In the context of rising artemisinin- and multidrug-
resistance, significant gains can still be achieved by 
making EDT available to everyone. The MP is a simple 
structure relying on three equally crucial components 
to provide EDT: RDTs, ACT+ primaquine, and trained 
and paid MPWs originating from the community. Set-
ting up, monitoring, supplying, and collecting activity 
data from MP in the hardest-to-reach malaria endemic 
areas represents a logistic and organizational chal-
lenge but will yield a major impact. A coordinated MP 
network can be expected to trigger a regional rapid 
decrease in falciparum malaria clinical case incidence 
and prevalence, a highly desirable outcome in a malaria 
elimination strategy. In addition to this generalized MP 
coverage, elimination could be quickened by a limited 
number of targeted interventions, such as mass-drug 
administration and adapted vector control in high-risk 
communities.
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